Tuesday, 02 January 2024 12:17 GMT
عربي


               US          Europe          Arab          Asia          Africa    
|      Politics          Economy     Oil&Energy         
                 Entertainment          Sport
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors To Secure Counsel Before Important Deadline In Securities Class Action IOVA

ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors To Secure Counsel Before Important Deadline In Securities Class Action IOVA


2025-06-25 12:05:33
(MENAFN- ACCESSWIRE) NEW YORK, NY / ACCESS Newswire / June 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Iovance class action, go to , call Phillip Kim, Esq. at 866-767-3653 or email

MENAFN25062025004220003708ID1109719912



ACCESSWIRE

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Tags

Label

Comments

No comment

Category

Date
Search